Showing 51-60 of 97 results for "".
- J&J Seeks FDA Approval for Pediatric Tremfya Indicationshttps://practicaldermatology.com/news/jj-seeks-fda-approval-pediatric-tremfya-indications/2468706/Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremfya (guselkumab), seeking approval for pediatric indications. Tremfya, the first approved monoclonal antibody IL-23 inhibitor that select
- J&J Expands Atopic Dermatitis Pipeline with Yellow Jersey Therapeutics Acquisitionhttps://practicaldermatology.com/news/jj-expands-ad-pipeline-yellow-jersey-therapeutics-125-billion-acquisition/2463207/Johnson & Johnson (J&J) has announced its plan to acquire Yellow Jersey Therapeutics (a subsidiary of Numab Therapeutics) for $1.25 billion in cash, according to a news release. The acquisition includes the bispecific antibody NM26, which is currently advancing to phase 2 studies f
- Guselkumab Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Colorhttps://practicaldermatology.com/news/tremfya-guselkumab-demonstrates-significant-and-rapid-scalp-psoriasis-clearance-in-people-of-color-in-new-large-phase-3b-study/2462218/At the Maui Derm Hawaii 2024 conference, Johnson & Johnson presented topline data from Cohort B in the Phase 3b VISIBLE study that demonstrated that TREMFYA® (guselkumab) showed rapid and significant clearance in moderate to severe scalp psoriasis (PsO) and significant improvement
- Biosimilar News: Samsung Bioepis Secures US License Date for Proposed Stelara Biosimilarhttps://practicaldermatology.com/news/biosimilar-news-samsung-bioepis-secures-us-license-date-for-proposed-stelara-biosimilar/2462165/Samsung Bioepis Co., Ltd. signed a settlement and license agreement with Johnson & Johnson settling all pending US patent litigation between the two companies and clearing the way for commercialization of Samsung Bioepis’ SB17, a proposed biosimilar of reference medicine Stelara&nb
- Protagonist Therapeutics JNJ-2113 Update: IL23-Blocker Advances Into Multiple Clinical Development Programs for PsO, UChttps://practicaldermatology.com/news/jnj-2113-update-il23-blocker-advances-into-multple-clinical-development-programs-for-pso-uc/2462054/Protagonist Therapeutics, Inc. will be eligible to receive $60 million in milestone payments in the fourth quarter for the advancement of JNJ-2113 (formerly known as PN-235) into multiple clinical development programs led by Janssen Biotech, Inc., a Johnson & Johnson company (Janssen), the Co
- Crown Laboratories Opens Expanded Production Facilityhttps://practicaldermatology.com/news/crown-laboratories-opens-expanded-production-facility/2461769/Crown Laboratories completed a 60,000-square-foot expansion at its manufacturing complex in Johnson City, Tennessee. A year in the making, the $7.5 million expansion project at Lafe Cox Drive increases manufacturing and warehouse space to support business growth. The appr
- Industry Vet Curtis Cluff Named President and CFO of BioPhotas Inc.https://practicaldermatology.com/news/industry-vet-curtis-cluff-named-president-and-cfo-of-biophotas-inc/2461378/Curtis Cluff is the new President and Chief Financial Officer BioPhotas Inc., manufacturers of the Celluma series of light therapy devices. In this newly created role, Mr. Cluff will report to Patrick Johnson, Chief Executive Officer and inventor of the Celluma. &quo
- To Keep Pace with Growth, Crown Builds Out Manufacturing Complexhttps://practicaldermatology.com/news/to-keep-pace-with-growth-crown-builds-out-manufacturing-complex/2461266/Crown Laboratories is adding 60,000 square feet to its manufacturing complex in Johnson City, TN. The facility is home to PanOxyl acne wash, Blue Lizard Australian Sunscreen, and Sarna anti-itch lotion. The additional 60,000 sq. ft. will bring the Lafe Cox Drive facility
- Tremfya Safe, Effective Across Broad Patient Subpopulations Through 5 Years: Analysishttps://practicaldermatology.com/news/tremfya-safe-effective-across-broad-patient-subpopulations-through-five-years-analysis/2461130/Tremfya® (guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson can provide a consistent, high degree of durable skin clearance through 5 years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO), based on an
- Janssen Launches VISIBLE Study of PsO in People of Colorhttps://practicaldermatology.com/news/janssen-launched-visible-study-of-pso-in-people-of-color/2461121/The Janssen Pharmaceutical Companies of Johnson & Johnson has initiated VISIBLE, a first-of-its-kind, large-scale prospective clinical study dedicated to people of color living with moderate to severe plaque and/or scalp psoriasis (PsO). VISIBLE will further evaluate the efficacy an